by: Parent Project Muscular Dystrophy
PTC Therapeutics has shared a statement on EMFLAZA availability during the coronavirus (COVID-19) crisis, stating that the supply of EMFLAZA will not be affected by the coronavirus (COVID-19). PTC reports that they are closely monitoring any shipping issues in the United States, which could have an impact of delivery of drugs to patients. If patients have questions, you can contact PTC Cares at 1-844-PTC-CARES (844-478-2227).
Read PTC Therapeutic’s Statement
We want to assure patients and health care providers that the supply of EMFLAZA will not be affected by the coronavirus (COVID-19). We have over a year’s supply of the drug in stock and available for delivery.
That said, we are closely monitoring shipping issues in the United States, which could have an impact of delivery of drugs to patients. We will update our patients and health care providers if challenges arise.
Providing safe treatments to our patients is our first priority. We know how important access to our therapies is for our patients and caregivers, which is why we are continually looking for ways to the best ways serve them.
Everything PTC does is dedicated to improving the lives of patients with rare, difficult-to-treat genetic diseases. For over 20 years, have been dedicated to providing new, innovative therapies to patients with rare disorders. We are determined to deliver on that commitment.
If patients have questions, they can contact PTC Cares at 1-844-PTC-CARES (844-478-2227).
